Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
Year: 2019
Type: article
Study design: Clinical Trial
Abstract: The multicohort, phase II, nonrandomized KEYNOTE-059 study evaluated pembrolizumab ± chemotherapy in advanced gastric/gastroesophageal junction cancer. Results from cohorts 2 and 3, evaluating first-line therapy, are presented. Patients ≥ 18 years old had previously untreated recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma. Cohort 3 (monotherapy) had programmed death receptor 1 combined positive score ≥ 1. Cohort 2 (combination therapy) received pembrolizumab 200 mg on day 1, cisplatin 80 mg/m 2 on day 1 (up to 6 cycles), and 5-fluorouracil 800 mg/m 2 on days 1–5 of each 3-week cycle (or capecitabine 1000 mg/m 2 twice daily in Japan). Primary end points were safety (combination therapy) and objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 by central review, and safety (monotherapy). In the combination therapy and monotherapy cohorts, 25 and 31 patients were enrolled; median follow-up was 13.8 months (range 1.8–24.1) and 17.5 months (range 1.7–20.7), respectively. In the combination therapy cohort, grade 3/4 treatment-related adverse events occurred in 19 patients (76.0%); none were fatal. In the monotherapy cohort, grade 3–5 treatment-related adverse events occurred in seven patients (22.6%); one death was attributed to a treatment-related adverse event (pneumonitis). The objective response rate was 60.0% [95% confidence interval (CI), 38.7–78.9] (combination therapy) and 25.8% (95% CI 11.9–44.6) (monotherapy). Pembrolizumab demonstrated antitumor activity and was well tolerated as monotherapy and in combination with chemotherapy in patients with previously untreated advanced gastric/gastroesophageal junction adenocarcinoma. ClinicalTrials.gov NCT02335411
Source: Gastric Cancer
Authors: Yung-Jue Bang, Yoon-Koo Kang, Daniel V. Catenacci, Kei Muro, Charles S. Fuchs, Ravit Geva, Hiroki Hara, Talia Golan, Marcelo Garrido, Shadia I. Jalal, Christophe Borg, Toshihiko Doi, Harry H. Yoon, Mary J. Savage, Jiangdian Wang, Rita P. Dalal, Sukrut Shah, Zev A. Wainberg, Hyun Cheol Chung
Institutions: Seoul National University, Asan Medical Center, University of Ulsan, University of Chicago, University of Chicago Medical Center, Aichi Cancer Center, Aichi Cancer Center Hospital, Yale Cancer Center, Tel Aviv University, Tel Aviv Sourasky Medical Center, Saitama Cancer Center, Sheba Medical Center, Pontificia Universidad Católica de Chile, Indiana University Indianapolis, Indiana University School of Medicine, Centre Hospitalier Universitaire de Besançon, National Cancer Center Hospital East, Mayo Clinic, Merck & Co., Inc., Rahway, NJ, USA (United States), University of California, Los Angeles, Yonsei University, Yonsei Cancer Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,760
OpenAlex ID: W2934520391
